Skip to main content

Table 1 Demographic characteristics

From: Reliability, repeatability, and reproducibility of pulmonary transit time assessment by contrast enhanced echocardiography

 

Mean ± SD (n = 15)

Min – max (n = 15)

Gender (n male/women)

12/3

 

Age (yr)

67 ± 7

58–78

Weight (kg)

81 ± 15

51–109

Height (cm)

176 ± 9

158–188

BMI

26 ± 4

19–37

BSA

2.0 ± 0.2

1.5–2.3

NYHA classification n (%)

  

Class II

7 (47)

 

Class III

5 (33)

 

Class IV

3 (20)

 

Echocardiography

  

  LVEF (%)

31 ± 11

17–53

  RV dysfunction

  

  TAPSE < 16 mm (n)

4/15

 

  Pulmonary hypertension

  

  TR velocity > 2.8 m/s (n)

2/15

 

Electrocardiogram

  

  Heart rate

72 ± 17

50–110

  QRS duration (ms)

151 ± 27

118–194

  IVMD (ms) in 13 patients

42 ± 14

20–60

  SPWMD (ms) in 11 patients

152 ± 70

10–240

Comorbidities n (%)

  

  Hypertension

5 (33)

 

  Coronary artery disease

11 (73)

 

  Congestive heart failure

14 (93)

 

  COPD

6 (40)

 

  Diabetes mellitus

3 (20)

 

Medication n (%)

  

  Beta-blocker

12 (80)

 

  ACE inhibitors

11 (73)

 

  AT II blockers

2 (13)

 

  Loop diuretics

12 (80)

 

  K-sparing agents

6 (40)

 

  Statins

14 (93)

 

Laboratory

  

  Creatinine (μmol/L)

105 ± 28

31–160

  NT-proBNP (pmol/L)

162 ± 111

36–440

  1. SD standard deviation, BMI body mass index, BSA body surface area, NYHA New York Heart Association, LVEF left ventricular ejection fraction, RV right ventricle, TAPSE tricuspid annular plane systolic excursion, TR tricuspid regurgitation, IVMD interventricular mechanical delay, SPWMD septal to posterior wall motion delay, COPD chronic obstructive pulmonary disease, ACE angiotensin-converting enzyme, AT II angiotensine-II-receptor antagonist, K-sparing potassium sparing, NT-proBNP N-terminal pro-B-type natriuretic peptide